2023
Birth characteristics and risk of Ewing sarcoma
Wiemels J, Wang R, Feng Q, Yee A, Morimoto L, Metayer C, Ma X. Birth characteristics and risk of Ewing sarcoma. Cancer Causes & Control 2023, 34: 837-843. PMID: 37335392, PMCID: PMC10460323, DOI: 10.1007/s10552-023-01737-4.Peer-Reviewed Original ResearchConceptsBirth characteristicsEwing's sarcomaConclusionsThis population-based studyDisease riskMultivariable logistic regression modelNon-Hispanic white subjectsPopulation-based seriesPopulation-based studySignificant risk factorsMetastatic Ewing sarcomaEwing's sarcoma casesMinimal selection biasLogistic regression modelsYear of birthPurposeThe incidenceFetal growthRisk factorsSarcoma casesLower riskSarcomaMultiethnic populationBirth recordsWhite subjectsGenetic susceptibilityPredisposition alleles
2022
Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL
Feng Q, Zhou M, Li S, Morimoto L, Hansen H, Myint SS, Wang R, Metayer C, Kang A, Fear AL, Pappas D, Erlich H, Hollenbach JA, Mancuso N, Trachtenberg E, de Smith AJ, Ma X, Wiemels JL. Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances 2022, 6: 3756-3766. PMID: 35500222, PMCID: PMC9631572, DOI: 10.1182/bloodadvances.2021006821.Peer-Reviewed Original ResearchConceptsKiller immunoglobulin-like receptorsMaternal killer immunoglobulin-like receptorsAcute lymphoblastic leukemiaChild-mother pairsImmunoglobulin-like receptorsArginase IIKIR interactionsLower riskNon-Latino white subjectsLower tumor necrosisCase-control studyEtiology of childhoodDevelopment of childhoodHLA-KIRNeonatal cytokinesCytokine levelsCytokine profileLymphoblastic leukemiaImmune factorsImmune phenotypeTumor necrosisHigh riskChildhood leukemiaCytokine controlSignificant association
2021
Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study
Dwyer KE, Wang R, Cozen W, Cartmel B, Wiemels JL, Morimoto LM, Metayer C, Ma X. Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: cebp.0535.2021. PMID: 34548330, DOI: 10.1158/1055-9965.epi-21-0535.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaT-cell non-Hodgkin lymphomaCase-control studyBirth characteristicsMode of deliveryYear of birthOdds ratioNHL riskUnconditional multivariable logistic regression modelsPopulation-based case-control studyCases of NHLMultivariable logistic regression modelConfidence intervalsAge of diagnosisPediatric Burkitt lymphomaLogistic regression modelsCesarean sectionHistologic subtypeDecreased riskHodgkin's lymphomaMaternal ageBurkitt's lymphomaElevated riskLower riskMaternal educationAnalysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database
Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerNational Cancer DatabaseColorectal cancerAge 51Overall survivalCancer DatabaseIncidence of CRCCox proportional hazards regressionPrimary colorectal cancerKaplan-Meier analysisProportional hazards regressionAge 50 yearsAge 25 yearsAnalysis of survivalCohort studySurvival benefitHazards regressionUnadjusted analysesCancer incidenceMAIN OUTCOMEAge 35Survival advantageLower riskStage I
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSImpact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2015
Birth weight, fetal growth, and risk of pediatric rhabdomyosarcoma: an updated record linkage study in California
Morimoto LM, McCauley K, Ma X, Wiemels JL, Chokkalingam AP, Metayer C. Birth weight, fetal growth, and risk of pediatric rhabdomyosarcoma: an updated record linkage study in California. Annals Of Epidemiology 2015, 26: 141-145. PMID: 26795698, DOI: 10.1016/j.annepidem.2015.11.007.Peer-Reviewed Original ResearchConceptsRisk of rhabdomyosarcomaHigh birth weightBirth weightGestational ageNon-Hispanic white childrenPost-term babiesCalifornia Cancer RegistryNormal gestational ageRecord linkage studyConditional logistic regressionCalifornia birth recordsNon-Hispanic whitesIndication of associationCancer RegistryBirth characteristicsFetal growthPediatric rhabdomyosarcomaRMS casesLower riskBirth recordsEthnic groupsLarger studyLogistic regressionWhite childrenAge